Scope and Claims Analysis for US Patent 12,419,937 (Pompe Disease: n-Butyl-Deoxynojirimycin Plus Acid α-Glucosidase)
US 12,419,937 covers a combination-treatment method for Pompe disease that co-administers (i) n-butyl-deoxynojirimycin (NB-DNJ) and (ii) acid α-glucosidase (GAA), with claim scope driven by (1) the presence of both active agents, (2) specific GAA concentration and dose ranges, and (3) selected formulation and route limitations. The independent claim (claim 1) is an administration method, not a product per se, and it is narrowed by GAA concentration (about 5 mg/mL to about 80 mg/mL) in a “second composition.” Dependent claims tighten dose (5–50 mg/kg; 10–40; 15–25; 20 mg/kg), buffer selection, excipient presence, and oral (NB-DNJ) plus intravenous (GAA) co-administration.
Given only the claim text provided, the analysis below focuses on claim construction, measurable infringement touchpoints, and how the defined parameters shape the enforceable scope and the competitive freedom-to-operate contours.
What is the exact claim scope of US 12,419,937 for Pompe combination therapy?
Claim 1 is the core scope. It requires all elements below in a single treating method:
- Treating Pompe disease in a subject.
- Administering a first composition comprising n-butyl-deoxynojirimycin (or a pharmaceutically acceptable salt).
- Administering a second composition comprising acid α-glucosidase (GAA).
- The GAA concentration in the second composition is about 5 mg/mL to about 80 mg/mL.
- Administering NB-DNJ and GAA in an amount effective to treat Pompe disease.
Key scope drivers
- Combination is mandatory: either agent alone does not fall within claim 1.
- Defined concentration window applies to GAA: the second composition must have GAA formulated at 5–80 mg/mL.
- Method-of-treatment claim: infringement hinges on what is administered to a treated subject, including formulation concentration, not just dosing schedules on paper.
What “administering in an amount effective for treating” means for enforcement
This is typical method language that can be satisfied by clinical effectiveness or by claimed ranges in dependent claims. Practically, enforceability usually turns on whether the regimen as used falls within the explicitly claimed formulation/dose parameters (concentration and mg/kg windows). The “effective amount” requirement is broader than a fixed dose range, but it does not eliminate the need to prove that the administered regimen treated Pompe.
How do the dependent claims narrow the GAA dosing and concentration ranges?
GAA concentration (independent claim 1)
- About 5 mg/mL to about 80 mg/mL (claim 1)
GAA concentration pinned to a specific value (claim 8)
- About 15 mg/mL in the second composition (claim 8)
GAA dosing ranges (claims 2–5 and 11–13)
- About 5 mg/kg to about 50 mg/kg (claim 2)
- About 10 mg/kg to about 40 mg/kg (claim 3)
- About 15 mg/kg to about 25 mg/kg (claim 4)
- About 20 mg/kg (claim 5)
Claims 11–13 mirror claims 1–4 but with an additional concentration requirement (see below).
Claim 11 adds a concentration limitation and repeats dosing windows
Claim 11 requires:
- NB-DNJ in first composition
- GAA in second composition
- GAA concentration about 15 mg/mL
- GAA dose about 5 mg/kg to about 50 mg/kg
Then:
- 15–25 mg/kg (claim 12)
- 20 mg/kg (claim 13)
Practical impact on scope:
The estate is bifurcated into (a) a broad concentration window (5–80 mg/mL) under claim 1, and (b) a narrower “fixed concentration” line at ~15 mg/mL under claim 8 and claim 11 family. A competitor could potentially design around the fixed-concentration claims while still falling within claim 1’s broader concentration range, or vice versa, depending on what concentration they use in the GAA infusion preparation and whether the regimen also matches the mg/kg dosing windows.
What formulation features are explicitly required (buffer and excipient limitations)?
Buffer requirement only in dependent claims
- Second composition further comprises a buffer (claim 6; and claim 14 for the claim 11 family)
- Buffer is selected from:
- citrate
- acetate
- bicarbonate
- phosphate
- or combinations (claims 7 and 15)
Excipient requirement
- At least one of the first composition and the second composition further comprises an excipient (claim 9; and claim 17)
Practical impact on infringement:
- If the accused regimen uses NB-DNJ and GAA at claimed concentration/dose ranges but uses no buffer in the GAA formulation, it may still infringe independent claim 1 but avoid buffer-dependent claims 6/7 (and 14/15).
- If the regimen uses only pharmaceutical compositions without “excipient” (rare in practice), it could avoid claims 9/17. In most marketed biologic infusion and oral formulations, excipients are typically present, meaning claims 9/17 are usually easy to satisfy.
How do the route-of-administration limitations affect the scope (oral NB-DNJ + IV GAA)?
Specific route limitation in dependent claims
- First composition administered orally
- Second composition administered intravenously (claim 10)
- Same structure in claim 18 (for claim 11 family)
Practical impact:
If a competitor administers NB-DNJ by another route (e.g., parenteral) or gives GAA by a non-IV route (unlikely given standard GAA delivery), it may avoid dependent claims 10/18 while still infringing independent claim 1 (and potentially claim 8/11 families depending on concentration and dose). Because claim 10/18 are dependent, their limitation is not required for claim 1.
What does the independent claim cover versus what it does not? (Inclusion and carve-out logic)
Covered by claim 1 if all are true
- Pompe treatment in a subject
- NB-DNJ (or salt) administered
- GAA administered
- GAA formulation concentration in the second composition is 5–80 mg/mL
- Administered regimen is in amounts effective to treat Pompe
Not covered by claim 1 if any element fails
- NB-DNJ is omitted (monotherapy)
- GAA is omitted
- GAA is formulated below ~5 mg/mL or above ~80 mg/mL in the “second composition”
- The method does not involve treating Pompe disease (e.g., use in another indication)
- The second composition does not contain GAA as “acid α-glucosidase” (not a different enzyme)
Covered by claim 8 (concentration-specific)
- Same as claim 1 plus GAA formulated at about 15 mg/mL
Covered by claim 11 (concentration-specific + dose window)
- Same as claim 1 but with GAA formulated about 15 mg/mL and dose 5–50 mg/kg
What is the measurable “infringement recipe” for US 12,419,937?
The claim is drafted for factual proof at the point of administration and formulation. The cleanest infringement case would establish:
- The patient is treated for Pompe disease.
- NB-DNJ (or salt) is administered as a first composition.
- GAA is administered as a second composition with measured/validated concentration in the stated window.
- The GAA dose is within the mg/kg bounds if asserting dependent claims 2–5 or 11–13.
- The oral/IV route is used if asserting dependent claims 10/18.
- Buffer identity and excipient presence are shown if asserting claims 6/7/9 or 14/15/17.
How does US 12,419,937 likely position against the core Pompe standard-of-care patent landscape (GAA replacement + substrate reduction)?
Substrate reduction track: NB-DNJ
The claim ties NB-DNJ to Pompe combination use. That creates an enforcement hook against any program that treats Pompe with NB-DNJ alongside IV GAA at stated formulation concentrations and doses.
Enzyme replacement track: acid α-glucosidase (GAA)
Because the claims specify GAA concentration (mg/mL) and, in dependent claims, GAA dose (mg/kg), they intersect with how IV GAA is reconstituted and diluted for infusion. Many FTO decisions in biologics hinge on whether the infusion concentration and dose match label or study practice.
Combination track: “co-formulated” as separate compositions
The patent does not require both actives in one composition. It requires two compositions: first for NB-DNJ, second for GAA. This is significant because it captures regimens where the therapies are administered separately by standard modalities while meeting concentration/dose constraints.
Which competitors are most exposed based on the claim parameters?
Exposure is highest where competitors:
- Use NB-DNJ (or a salt) for Pompe,
- Administer IV GAA,
- Use GAA infusion solutions in the stated 5–80 mg/mL concentration range, and
- Use GAA doses overlapping 5–50 mg/kg and narrower windows (10–40; 15–25; 20 mg/kg).
Competitors that omit NB-DNJ are outside the claims. Competitors that use NB-DNJ but adjust infusion concentration outside 5–80 mg/mL, or adjust dose outside the dependent ranges (while also avoiding the independent claim’s 5–80 mg/mL requirement), would reduce risk. Competitors that use NB-DNJ with GAA at ~15 mg/mL are particularly exposed to claim 8 and claim 11-family claims.
What generic entry risks exist if this is treated as a method-of-use combination patent?
Because the patent is a method of treating Pompe disease using a defined formulation concentration/dose regimen, “generic entry” is not about substituting NB-DNJ or GAA in the traditional small-molecule sense. The risk instead maps to:
- biosimilar substitution for GAA (if a biosimilar is used in the same infusion concentration/dose regimen), and/or
- substitution of NB-DNJ with an equivalent salt/formulation (if it is still “n-butyl-deoxynojirimycin or a pharmaceutically acceptable salt thereof”).
If a biosimilar or an alternate GAA product is administered in the same way, the method claim can still be implicated if all elements are satisfied.
How strong is the likely patent estate strength from the claim drafting style?
From the claims alone, the estate appears engineered for enforceability via:
- A clear combination requirement (NB-DNJ + acid α-glucosidase).
- Quantitative formulation constraints (GAA concentration ranges; explicit ~15 mg/mL).
- Quantitative dosing constraints (mg/kg windows including a single-point 20 mg/kg).
- Factual, operational proof targets (formulation concentration in the second composition; route; buffer).
- Layered dependent claims that let enforcement proceed at different granularity levels: broader independent claim 1 for general combination regimens; narrower dependent claims for specific dilution or clinical dosing schedules.
This structure often improves settlement leverage because parties can test whether their regimen matches any layer of the claim set.
Does US 12,419,937 cover combination regimens delivered on fixed schedules or only “effective amounts”?
The independent claims do not specify administration timing or frequency. That leaves method scope broad with respect to schedule, as long as the method includes administering the compositions and the concentration/dose constraints apply. Dependent claims likewise do not set dosing frequency, only amount and formulation properties. That reduces design-around opportunities that rely on changing schedule alone.
Timeline and exclusivity analysis: what matters for enforcement timing?
Only the claim text is provided; no filing date, priority date, prosecution history, or listed expiration is available here. As a result, no enforceability window can be stated. What can be inferred structurally is that enforcement depends on patent expiration and any PTA adjustments, and on whether the regimen practiced by an accused party falls within the concentration/dose limits.
Key limitations that a challenger would typically test (design-around levers)
These are the most obvious “knobs” appearing in the claims:
- GAA concentration
- For claim 1: keep GAA formulation concentration outside about 5–80 mg/mL
- For claim 8/11: keep outside about 15 mg/mL
- GAA dose (for dependent claims)
- Avoid 5–50 mg/kg (claim 2/11)
- Avoid 10–40 (claim 3/16)
- Avoid 15–25 (claim 4/12)
- Avoid 20 mg/kg (claim 5/13)
- Buffer composition
- Avoid buffer or use non-listed buffer species (to avoid claims 6/7/14/15)
- Route-of-administration
- Avoid oral NB-DNJ or IV GAA as specified (to avoid claims 10/18)
Because claim 1 does not require buffer/excipients/route, the concentration condition and the presence of both actives are the hardest core elements.
Key Takeaways
- US 12,419,937 is a Pompe method-of-treatment combination patent requiring NB-DNJ and acid α-glucosidase together in treating the subject.
- Claim 1 is anchored by a measurable GAA formulation concentration requirement: about 5–80 mg/mL in the second composition.
- Claims 8 and 11 add a high-specificity anchor at about 15 mg/mL, increasing exposure for regimens that use that exact concentration.
- Dependent claims narrow enforceable territory via GAA dose ranges (including 20 mg/kg as a single-point claim), buffer species, excipient presence, and oral/IV routes.
- The most reliable infringement proof will focus on what was administered and how it was prepared: NB-DNJ as a first composition; GAA as a second composition meeting concentration (and dose for dependent claims) requirements.
FAQs
-
Does US 12,419,937 require a single formulation containing both n-butyl-deoxynojirimycin and acid α-glucosidase?
No. It requires administering two compositions: one for NB-DNJ and one for acid α-glucosidase.
-
What is the most important numerical limitation for claim 1 of US 12,419,937?
The GAA concentration in the second composition must be about 5 mg/mL to about 80 mg/mL.
-
Which dependent claims are triggered by using GAA at about 15 mg/mL?
Claim 8 (and the claim 11 family, including claims 11–13).
-
Can a company avoid dependent claims by changing the route of administration while still using the same combination?
Route changes can avoid dependent claims 10/18, but they do not avoid claim 1 unless other core limitations are also changed (actives present and GAA concentration within the claimed window).
-
Is this patent limited to specific dosing frequency or treatment schedule?
The provided claims do not specify frequency or timing; they focus on administering the compositions in effective amounts with the stated formulation and dose parameters.
References
- United States Patent 12,419,937, claims 1–18 (as provided in the prompt).
